Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

Celera and Medco collaborate in KIF6 gene variant testing

Celera Corporation (NASDAQ:CRA) and Medco Health Solutions, Inc. (NYSE:MHS), today announced that they have entered into a research collaboration to evaluate whether testing for a gene variant called KIF6 increases patient adherence with statin therapy. Current studies have suggested that only about 50 to 60 percent of the patients who receive a prescription for a lipid-lowering drug are taking the medication after six months.

23 Sep 2009

Researchers to present results of HORIZONS-AMI trial at TCT scientific symposium

Two subset analyses from the landmark HORIZONS-AMI trial show that the anticoagulant bivalirudin lowers major bleeding and cardiac death versus the combination of heparin and a GP IIb/IIIa inhibitor in patients with ST-segment myocardial infarction (STEMI) who have disease of the left anterior descending artery (LAD), while in STEMI patients at highest risk for death, bivalirudin also confers the greatest mortality benefit.

22 Sep 2009

New sirolimus-eluting stent shows greater neointimal suppression than PES

A new type of sirolimus-eluting stent (SES) successfully showed significantly greater neointimal suppression than the paclitaxel-eluting stent (PES) with greater vessel wall integrity surrounding the stent, confirming the finding of superiority of the SES over the PES stent for the trial's primary endpoint of in-stent late loss.

22 Sep 2009

New wireless Fractional Flow Reserve system to evaluate blood flow blockages in the arteries

St. Jude Medical, Inc. (NYSE: STJ) today announced the first use of the PressureWire™ Aeris technology, an interventional tool which measures Fractional Flow Reserve (FFR) to evaluate the severity of blood flow blockages in the arteries. This first-to-market technology helps interventional cardiologists better determine the ideal treatment option for their patients during coronary interventions, such as stent procedures.

22 Sep 2009

FDA approves Cordis Corporation's 2.25 mm CYPHER Stent

Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for a new, smaller version of the CYPHER® Sirolimus-eluting Coronary Stent, the world’s most studied drug-eluting stent that has been used to treat nearly 4 million people worldwide. The new 2.25 mm CYPHER® Stent is indicated for treatment of coronary blockages in small vessels, an often difficult-to-treat situation.

22 Sep 2009

XIENCE V Everolimus Eluting Coronary Stent System exhibits its advantages over the TAXUS system

Long-term data presented today from the SPIRIT III pivotal U.S. clinical trial demonstrated that the observed clinical advantages of Abbott's market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System continued to increase as compared to the TAXUS(R) Express2 Paclitaxel-Eluting Coronary Stent System (TAXUS).

21 Sep 2009

Medtronic to showcase cardiovascular product portfolio at TCT 2009

Expecting new data on drug-eluting stents and transcatheter heart valves to feature prominently at Transcatheter Cardiovascular Therapeutics (TCT) 2009 next week in San Francisco, Medtronic, Inc. (NYSE: MDT), today announced plans to showcase its innovative cardiovascular product portfolio, technology pipeline and clinical research at the world’s premier annual meeting for interventional cardiologists.

19 Sep 2009

Treatment costs for diabetes care are higher in Texas than other states

The Texas Business Group on Health (TBGH), a non-profit business association, today released its annual report on the prevalence, cost and quality of care for Texans with Type 2 diabetes.

18 Sep 2009

Comprehensive CT scan gives better indication of significant coronary artery disease

A team of researchers led by Massachusetts General Hospital (MGH) radiologists has developed a computed-tomography-based protocol that identifies both narrowing of coronary arteries and areas of myocardial ischemia - restricted blood flow to heart muscle tissue - giving a better indication of clinically significant coronary artery disease.

16 Sep 2009

Tryton Side Branch Stent used in 250 procedures to treat atherosclerotic lesions

Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, announced today that the company’s Tryton Side Branch Stent has been used in 250 procedures to treat atherosclerotic lesions at a bifurcation in patients with heart disease.

15 Sep 2009

Texas Cardiac Arrhythmia Institute to utilize Odyssey systems

Stereotaxis, Inc., announced that the Texas Cardiac Arrhythmia Institute at St. David's Medical Center in Austin, Texas ordered four Odyssey(TM) systems.

15 Sep 2009

Public health policy should stress on reduction in sodium intake

Reducing sodium intake is a major public health priority that must be acted upon by governments and nongovernmental organizations to improve population health, states an article http://www.cmaj.ca/press/cmaj090361.pdf in CMAJ (Canadian Medical Association Journal) www.cmaj.ca.

15 Sep 2009

Chinese SFDA approves Abbott's XIENCE V drug eluting stent for treating coronary artery disease

Abbott (NYSE: ABT) announced today that the Chinese State Food and Drug Administration (SFDA) has approved its XIENCE V(R) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease (CAD) - the leading cause of death in China. XIENCE V is the only drug eluting stent to have demonstrated superiority over the TAXUS(R) Paclitaxel-Eluting Coronary Stent System (TAXUS) in the primary endpoints of two randomized, pivotal (phase III) clinical trials.

14 Sep 2009

First patient enrolled in Phase 2b RADAR clinical trial

Regado Biosciences, a privately held company leading the development of antithrombotic therapeutic aptamers with active control agents, announced that on September 8, 2009 enrollment of the first patient in a Phase 2b, randomized, partially-blinded, multi-center, active-controlled, dose-ranging study of its lead product candidate, the REG1 anticoagulation system (REG1) was achieved.

11 Sep 2009

Merck update on the status of telcagepant clinical development programs

Merck & Co., Inc. today updated the status of the clinical development programs for telcagepant (MK-0974) and MK-3207, the Company's investigational oral calcitonin gene-related peptide (CGRP) receptor antagonists for the intermittent treatment of acute migraine.

11 Sep 2009

Abbott to acquire Evalve for $410 million

Abbott announced today a definitive agreement to acquire the outstanding equity of Evalve, Inc., the global leader in the development of devices for minimally invasive repair of cardiac mitral valves.

10 Sep 2009

Endothelin research update to be presented at APS' 11th International Conference

Recent research to block the effects of endothelin, a powerful substance that constricts blood vessels and stimulates cell growth, has led to successful treatment of pulmonary arterial hypertension and provides hope for treating other chronic diseases.

10 Sep 2009

Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

Celera and Medco collaborate in KIF6 gene variant testing

Researchers to present results of HORIZONS-AMI trial at TCT scientific symposium

New sirolimus-eluting stent shows greater neointimal suppression than PES

New wireless Fractional Flow Reserve system to evaluate blood flow blockages in the arteries

FDA approves Cordis Corporation's 2.25 mm CYPHER Stent

XIENCE V Everolimus Eluting Coronary Stent System exhibits its advantages over the TAXUS system

Medtronic to showcase cardiovascular product portfolio at TCT 2009

Treatment costs for diabetes care are higher in Texas than other states

Comprehensive CT scan gives better indication of significant coronary artery disease

Tryton Side Branch Stent used in 250 procedures to treat atherosclerotic lesions

Texas Cardiac Arrhythmia Institute to utilize Odyssey systems

Public health policy should stress on reduction in sodium intake

Chinese SFDA approves Abbott's XIENCE V drug eluting stent for treating coronary artery disease

First patient enrolled in Phase 2b RADAR clinical trial

Merck update on the status of telcagepant clinical development programs

Abbott to acquire Evalve for $410 million

Endothelin research update to be presented at APS' 11th International Conference

U.S patent for Tryton Side Branch Stent System

Cardiac Network increases the number of sites for its research study

Research study examines the depression rate in chronic kidney disease patients

Innovation in neuroscience drug discovery - eBook eBook

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

Innovation in neuroscience drug discovery - eBook eBook

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Newsletters you may be interested in